Author

S. A. Carratt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

J. E. Maxson· 3 shared T. P. Braun· 3 shared Z. Schonrock· 3 shared A. Foley· 2 shared B. J. Druker· 2 shared B. M. Smith· 2 shared C. Coblentz· 2 shared L. Maloney· 2 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. E. Maxson

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Mutant-SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms

S. A. Carratt, G. L. Kong, B. M. Smith, Z. Schonrock, L. Maloney, A. Baris, B. J. Druker, T. P. Braun, J. E. Maxson

This study shows that mutant SETBP1 promotes aggressive myeloproliferative neoplasms by upregulating Myc and its target genes, which can be reversed by epigenetic drugs.

bioRxiv · Nov 4, 2021Cancer Biology

Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia

S. A. Carratt, T. P. Braun, C. Coblentz, Z. Schonrock, R. Callahan, B. M. Smith, L. Maloney, A. Foley, J. E. Maxson

This study shows that SETBP1 mutations enhance NRAS-driven MAPK signaling in leukemia, making cells sensitive to MEK inhibitor trametinib.

bioRxiv · Feb 1, 2021Cancer Biology

Myeloid Lineage Enhancers Drive Oncogene Synergy in CEBPA/CSF3R Mutant Acute Myeloid Leukemia

T. P. Braun, M. Okhovat, C. Coblentz, S. A. Carratt, A. Foley, Z. Schonrock, K. Nevonen, B. Davis, B. Garcia, D. LaTocha, B. R. Weeder, M. R. Grzadkowski, J. C. Estabrook, H. G. Manning, K. Watanabe-Smith, , J. E. Maxson

The paper identifies mutation synergy between CSF3R and CEBPA in AML, showing their interaction at myeloid lineage enhancers and the requirement of CEBPA mutations as an initial event.

bioRxiv · May 15, 2019Cancer Biology